Co-mutation analyses revealed recurrent <i>PTEN</i> partnerships with <i>TP53</i>, <i>EGFR</i>, and <i>APC</i> in LUAD, with <i>PTEN-TP53</i> co-alterations enriched in metastatic disease. Here, PTEN is linked to metastatic neoplasm.